



**AWMSG ADVICE SUPERSEDED BY  
NICE GUIDANCE (TA449)  
NICE GUIDANCE ISSUED JUNE 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation**

**Sunitinib (Sutent<sup>®</sup>)  
Submission by:  
Pfizer Ltd**

**Advice No: 1111 – September 2011**

**Recommendation of AWMSG**

Sunitinib (Sutent<sup>®</sup>) is recommended for use within NHS Wales for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. Experience with sunitinib as a first-line treatment is limited.

AWMSG is of the opinion that sunitinib (Sutent<sup>®</sup>) is not suitable for shared care within NHS Wales for the above indication.

**Additional notes:**

The AWMSG recommendation has been based on an approved patient access scheme.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: